The PPARγagonist rosiglitazone attenuated TNBS-induced colitis via inhibition of theactivity of the MAPKs p38 and the c-Jun N-terminal kinase (JNK), and of NF-κB,thereby limiting the expression of proinflammatory genes [95]. The gene discussed is MAPK8; the disease is colitis.